Mohammed Haneefa Nizamudeen/iStock via Getty Images
Acelirine (NASDAQ: SLRN) shares traded higher on Friday after the company scheduled an investor meeting for next week to discuss updated data from a Phase 2 trial of lonigutamab, an injection targeted for thyroid eye disease (TED).
In the virtual event,
